NLS Pharmaceutics Ltd.

NLSP

CH0523961370

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 24/05/2024 am IST			5-day change	1st Jan Change
0.1734 ^USD	+8.41%		+16.06%	-70.61%

08/04	Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors	CI
03/04	NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding	CI

Presenter SpeechErik Carlson (Attendees)Welcome to NLS Pharmaceuticals. They are seeking to de...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about NLS Pharmaceutics Ltd.

Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors	09/04	CI
NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding	03/04	CI
NLS Pharmaceutics Ltd. announced that it expects to receive $1.75 million in funding	20/03	CI
NLS Pharmaceutics Files Plan to Regain Nasdaq Listing Compliance	23/02	MT
NLS Pharmaceutics AG Reports Earnings Results for the Half Year Ended June 30, 2023	07/12	CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	02/12	MT
Sector Update: Health Care Stocks Rise in Afternoon Trading	02/12	MT
Top Midday Gainers	02/12	MT
NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise	01/12	MT
NLS Pharmaceutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value	17/11	CI
Maxim Downgrades NLS Pharmaceutics to Hold From Buy	14/23/14	MT
Top Premarket Gainers	31/23/31	MT
NLS Pharmaceutics Ltd. cancelled the transaction announced on August 19, 2022	19/23/19	CI
Sector Update: Health Care Stocks Steady Pre-Bell Monday	03/23/03	MT
NLS Pharmaceutics' Mazindol ER Trial to Move to Phase 3	03/23/03	MT
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol	03/23/03	CI
NLS Pharmaceutics Ltd. Approves Board Appointments	01/23/01	CI
NLS Pharmaceutics Says Drug Interaction Studies of Mazindol Show 'Positive Results'	14/23/14	MT
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol	14/23/14	CI
NLS Pharmaceutics AG Announces Executive Changes	25/23/25	CI
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer	08/23/08	CI
NLS Pharmaceutics Ltd. Announces the Resignation of Chad Hellmann as Chief Financial Officer	06/23/06	CI
NLS Pharmaceutics AG Reports Earnings Results for the Full Year Ended December 31, 2022	06/23/06	CI
NLS Pharmaceutics Receives Green Light from the U.S. Food and Drug Administration to Proceed with Phase 3 Clinical Program for Quilience(R) for the Treatment of Narcolepsy	02/23/02	CI
NLS Pharmaceutics Ltd. Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2	27/23/27	CI

NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NLS PHARMACEUTICS LTD.	-70.61%	8.17M
MODERNA, INC.	+64.92%	62.86B
IQVIA HOLDINGS INC.	-1.85%	41.38B
LONZA GROUP AG	+45.26%	40.38B
CELLTRION, INC.	-8.93%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	18.9B
BIO-TECHNE CORPORATION	+4.21%	12.67B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.27B
MEDPACE HOLDINGS, INC.	+27.42%	12.07B